In a report released today, Debanjana Chatterjee from JonesTrading reiterated a Buy rating on Clearside Biomedical (CLSD – Research Report), with a price target of $6.00.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Debanjana Chatterjee’s rating is based on several positive indicators for Clearside Biomedical. The company is actively seeking partnerships to support the pivotal program for CLS-AX in treating wet AMD, which could provide significant financial backing and strategic advantages. Additionally, CLS-AX is expected to receive a flexible label allowing for redosing, which aligns with existing anti-VEGF treatments but offers superior durability compared to leading competitors like Roche’s Vabysmo and Regeneron’s Eylea-HD.
Furthermore, CLS-AX stands out from other treatment candidates due to its ability to support flexible redosing without the need for additional anti-VEGF treatments. Despite having a competitive Phase 3-ready asset, Clearside Biomedical’s stock is currently undervalued compared to its peers, presenting a potential investment opportunity. The anticipated announcement of partnerships and a clear funding strategy for Phase 3 could significantly boost the company’s market position, justifying the Buy rating and a price target of $6.
In another report released today, Stifel Nicolaus also maintained a Buy rating on the stock with a $8.00 price target.